BOC Sciences offers the synthesis of a variety of backbone modified oligonucleotides, to increase the affinity of the oligonucleotide for its complementary strand, which often significantly improves the specificity and sensitivity of applications that detect small or highly similar DNA or RNA targets. These backbone modified oligonucleotides not only provide strong affinity enhancement, but also increase resistance to endonucleases and exonucleases, resulting in high in vitro and in vivo stability.
The oligonucleotide backbone consists of phosphodiester linkages and sugar moieties, which can be properly modified to improve the properties of various oligonucleotides, including improved stability to nuclease and uptake into cells, increased affinity for complementary strands, enhanced kinetics and base pairing specificity and sensitivity to binding to nucleic acid targets.
The synthesis of phosphorothioate oligonucleotides is achieved by replacing the non-bridging oxygen in the phosphate backbone of the oligonucleotide with a sulfur atom. PS-linkage modification has two excellent advantages. The first is to increase the stability of nuclease digestion. This modification will prolong the half-life of the oligonucleotide sequence and prevent its degradation. The second is to enhance the binding of proteins, especially serum proteins. Serum interactions include high-affinity interactions with heparin-binding proteins and low-affinity interactions with albumin. Increased binding to serum proteins retains circulating oligonucleotides, slows hepatic clearance, and prolongs absorption into target tissues. These advantages have led to their widespread use in the manufacture of first-generation antisense oligonucleotides (ASOs), which are designed to inhibit the expression of target RNAs through sequence-specific recognition. However, ASOs have the significant disadvantage of being severely toxic and prone to apoptosis.
The two non-bridging oxygen atoms of the oligonucleotide are replaced by sulfur atoms. These linkages are achiral and are fully resistant to cleavage by all known nucleases. However, phosphorodithioate-modified oligonucleotides are less used due to their reduced recognition ability when combined with complementary oligonucleotides, and can also bind to various proteins.
Methylphosphonate oligodeoxynucleotides (MPO), a metabolically stable analogue of conventional DNA, contain a methyl group replacement for a non-bonded phosphoryl oxygenate. This modification imparts a neutral charge to the methyl phosphonate backbone linkage. Oligonucleotides containing one or more methylphosphonate bonds will resist nuclease degradation at these sites, while the lack of charge will improve intracellular transport. Based on these properties, MPO has been explored as antisense reagents.
Ribose can be modified by replacing the 2'-hydroxyl group with different groups, but the most common are 2'-O-methyl, 2'-O-methoxyethyl and 2'-fluorine. The 2' ribose modification enhanced stability to nuclease digestion by blocking the nucleophilic 2' hydroxyl moiety. These modifications also increase the thermal stability of complementary hybridization, promote tighter binding and allow the use of shorter oligonucleotides. The fully modified oligonucleotide at the 2' position does not support RNase H activity and therefore is not cleaved, this property that allows it to be employed to protect mRNA targets and is currently exploited to design oligomers that regulate alternative splicing. The modifications at the 2' position are well tolerated in oligonucleotide duplexes, which enable the 2'-position to bind various functional groups, such as fluorophores.
The oligodeoxynucleotide replaces the phosphodiester (PO) group with a methanesulfonyl (methanesulfonyl) phosphoramidate group and exhibits high affinity for RNA, excellent resistance to nucleases, efficient recruitment of RNase H, and higher efficiency in catalyzing the degradation of oncogenic microRNAs (miRNAs). These remarkable features have led to its application in creating improved ASOs with potent anticancer effects.
The 2'-oxygen can also bind to the 4'-carbon of the ribose by bridging the carbon to form BNA. The first generation of BNAs are locked nucleic acids (LNAs) characterized by the presence of a covalent bond between the 2' oxygen and 4' carbon in the ribose. BNAs can readily bind to oligonucleotide chains, which can improve hybridization strength. BNA oligonucleotides show better base stacking and thermal stability, leading to extremely efficient binding to complementary nucleic acids and upgraded mismatch recognition. The introduction of a single BNA substitution can increase the melting temperature by 5-10°C, allowing the affinity for complementary hybridization to be tailored for clinical applications. BNA oligonucleotides also exhibit enhanced resistance to nucleases and are easily labeled or modified with standard oligonucleotide tags such as DIG, fluorescent dyes, biotin, amino adapters, etc. BNA oligos have been successfully used for single nucleotide polymorphism (SNP) detection and analysis, primer and probe design, and in antigene technology.
Modifications | Nuclease Resistance | RNase H Activation | Price |
Bridged Nucleic Acids (BNA) | Inquiry | ||
2' Fluoro RNA | Inquiry | ||
2' O-Methyl RNA (2'OMe) | Inquiry | ||
2'-F-ANA | Inquiry | ||
L-DNA | Inquiry | ||
L-RNA | Inquiry | ||
Phosphorothioate DNA | Inquiry | ||
Phosphorothioate RNA | Inquiry | ||
Phosphonoacetate (PACE) | Inquiry | ||
Methylphosphonate linkages | Inquiry | ||
ZNA Spermine | Inquiry |
Our oligonucleotide backbone modification synthesis services provide:
References
GMP Oligonucleotide Manufacturing Service
For more than 15 years, BOC Sciences has been manufacturing oligonucleotides for pre-clinical, pharmaceutical, food safety, and animal health industries. We provide customized and flexible oligonucleotide GMP or non-GMP production services to meet different production needs.
Lipid Nanoparticle(LNP) for RNA Delivery
BOC Sciences offers comprehensive LNP- mRNA delivery services tailored to meet the specific needs of mRNA vaccine development. Our expertise in nanoparticle formulation and mRNA chemistry enables us to design custom LNP formulations optimized for stability, efficacy, and safety.
BOC Sciences promises to offer you with GalNAc-siRNA conjugation services to help you conduct further research on GalNAc-siRNA conjugates and explore their mores omnics capabilities, the working mechanism as well as their potential therapeutic profiles.
BOC Sciences offers aptamer customization services to generate high-quality aptamers tailored to your goals, delivering excellent results even for the most difficult target molecules.
Peptide-Oligonucleotide Conjugation
BOC Sciences is committed to providing our customers with comprehensive modification and labeling, offering affordable custom oligonucleotides or peptide-oligonucleotide conjugates.